Summary of 3 randomized trials
| . | GITMO6,7 . | Finke8,9 . | Kröger10 . | Total . | RR . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | ATG . | noATG . | ATG . | noATG . | ATG . | noATG . | ATG . | noATG . | ||
| Patients, n | 56 | 53 | 103 | 98 | 83 | 72 | 242 | 223 | — | — |
| aGVHD II-IV, % | 50% | 70% | 33% | 51% | 11% | 18% | 31% | 46% | 1.47 | .001 |
| aGVHD III-IV, % | 23% | 43% | 11% | 24% | 2% | 8% | 12% | 25% | 2.08 | .0003 |
| cGVHD, % | 37% | 60% | 26% | 50% | 22% | 46% | 28% | 52% | 1.83 | .00001 |
| ext cGVHD, % | 15% | 41% | 12% | 45% | 5% | 24% | 11% | 37% | 3.43 | .00001 |
| NRM, % | 39% | 47% | 19% | 33% | 14% | 12% | 24% | 31% | 1.27 | .1 |
| Relapse, % | 23% | 21% | 33% | 28% | 32% | 25% | 29% | 25% | 0.84 | .2 |
| Survival, % | 55% | 56% | 55% | 43% | 74% | 77% | 61% | 59% | 1.04 | .6 |
| . | GITMO6,7 . | Finke8,9 . | Kröger10 . | Total . | RR . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | ATG . | noATG . | ATG . | noATG . | ATG . | noATG . | ATG . | noATG . | ||
| Patients, n | 56 | 53 | 103 | 98 | 83 | 72 | 242 | 223 | — | — |
| aGVHD II-IV, % | 50% | 70% | 33% | 51% | 11% | 18% | 31% | 46% | 1.47 | .001 |
| aGVHD III-IV, % | 23% | 43% | 11% | 24% | 2% | 8% | 12% | 25% | 2.08 | .0003 |
| cGVHD, % | 37% | 60% | 26% | 50% | 22% | 46% | 28% | 52% | 1.83 | .00001 |
| ext cGVHD, % | 15% | 41% | 12% | 45% | 5% | 24% | 11% | 37% | 3.43 | .00001 |
| NRM, % | 39% | 47% | 19% | 33% | 14% | 12% | 24% | 31% | 1.27 | .1 |
| Relapse, % | 23% | 21% | 33% | 28% | 32% | 25% | 29% | 25% | 0.84 | .2 |
| Survival, % | 55% | 56% | 55% | 43% | 74% | 77% | 61% | 59% | 1.04 | .6 |
ext, extensive; GITMO, Italian Cooperative Transplant Group; NRM, non-relapse mortality; RR, relative risk of patients not receiving ATG as compared with ATG.